Detalles de la búsqueda
1.
Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer.
Invest New Drugs
; 32(5): 955-68, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24942404
2.
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.
Cell Rep
; 22(11): 2978-2994, 2018 03 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-29539425
3.
LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
Oncotarget
; 8(6): 9251-9266, 2017 Feb 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27999210
4.
Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.
Cancer Discov
; 6(3): 300-15, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26732095
5.
Myostatin Neutralization Results in Preservation of Muscle Mass and Strength in Preclinical Models of Tumor-Induced Muscle Wasting.
Mol Cancer Ther
; 14(7): 1661-70, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25908685
6.
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
Cancer Cell
; 28(3): 384-98, 2015 Sep 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-26343583
7.
The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.
Mol Cancer Ther
; 13(10): 2253-63, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25122067
8.
Tasisulam sodium, an antitumor agent that inhibits mitotic progression and induces vascular normalization.
Mol Cancer Ther
; 10(11): 2168-78, 2011 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-21903607
Resultados
1 -
8
de 8
1
Próxima >
>>